FDA Approves First Interchangeable Biosimilar Insulin Product For Treatment Of Diabetes, Can Be Substituted At The Pharmacy

On July 29, 2021, the U.S. Food and Drug Administration (FDA) approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric consumers with Type 1 diabetes mellitus and in adults with Type 2 diabetes mellitus

Semglee (insulin glargine-yfgn), co-developed by Biocon Biologics and Viatris is both biosimilar to, and interchangeable with (can be substituted for), its reference product Lantus (insulin glargine), a long-acting insulin analog. Approval of these insulin products can provide consumers with additional safe, high-quality and potentially cost-effective options for treating diabetes.

Semglee is the first . . .